Document is current
Any future updates will be listed below
-
Authors
Ng, Benjamin https://orcid.org/0000-0001-8970-0932
Huang, Kevin Y.
Pua, Chee Jian https://orcid.org/0000-0003-4683-3043
Viswanathan, Sivakumar https://orcid.org/0000-0002-9263-1656
Lim, Wei-Wen https://orcid.org/0000-0003-0311-943X
Kuthubudeen, Fathima F. https://orcid.org/0000-0002-2821-5068
Liu, Yu-Ning https://orcid.org/0009-0001-9121-2732
Hii, An An https://orcid.org/0000-0003-2106-1876
George, Benjamin L. https://orcid.org/0000-0001-7887-2333
Widjaja, Anissa A. https://orcid.org/0000-0001-9404-7608
Petretto, Enrico https://orcid.org/0000-0003-2163-5921
Cook, Stuart A. https://orcid.org/0000-0001-6628-194X
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC-OFYIRG21jun-0022)
- License Information
-
More Information
Article History
Received: 13 December 2022
Accepted: 19 September 2024
First Online: 2 October 2024
Competing interests
: S.A.C. is a co-inventor of the patent applications (WO/2017/103108) and (WO/2018/109170). S.A.C., W.-W.L., and B.N. are co-inventors of the patent application (WO/2019/073057). S.A.C. is a co-founder and shareholder of Enleofen Bio PTE LTD, a company that develops anti-IL11 therapeutics, which were acquired for further development by Boehringer Ingelheim. The remaining authors declare no competing interests.
